Chief Financial Officer · Tarsus Pharmaceuticals, Inc. (TARS)

Leonard Greenstein

FY2023 is the first fiscal year CompBrief holds for Leonard Greenstein as a named executive officer of Tarsus Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,978,579

Salary $202,100Stock awards $411,746

3rd of 4 named executive officers at Tarsus Pharmaceuticals by FY2023 total.

4 named officers on file for Tarsus Pharmaceuticals, FY2023

Leonard Greenstein’s pay file — $29

  • 1 fiscal year of pay, line by line
  • TARS’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Tarsus Pharmaceuticals’s whole pay program stands against its peers

  • Tarsus Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TARS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Leonard Greenstein’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Leonard Greenstein compensation by year

Tarsus Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Tarsus Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$202,100
Bonus$0
Stock awards$411,746
Option awards$893,298
Non-equity incentive$71,552
Pension and deferred compensation$0
All other$399,883
Total$1,978,579

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Tarsus Pharmaceuticals, Inc. DEF 14A filed April 26, 2024, accession 0001819790-24-000056, and prior-year filings.

How this page was built: the Tarsus Pharmaceuticals, Inc. filed document, accession 0001819790-24-000056. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Tarsus Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Jeffrey FarrowChief Financial Officer and Chief Strategy Officer$3,991,830
Bobak AzamianPresident, Chief Executive Officer and Board Chairman$3,130,332
Leonard Greenstein · this pageChief Financial Officer$1,978,579
Seshadri NeervannanChief Operating Officer$1,741,918

The full Tarsus Pharmaceuticals compensation record

free company brief

This page is one person within Tarsus Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Tarsus Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Leonard Greenstein's compensation dossier · One-time report. No refunds.